CDEK
← All drugs Report issue

cotinine

Small moleculeexperimental

Cotinine is an alkaloid found in tobacco and is also the predominant metabolite of nicotine, typically used as a biomarker for exposure to tobacco smoke. Cotinine is currently being studied as a treatment for depression, post-traumatic stress disorder (PTSD), schizophrenia, Alzheimer's disease and Parkinson's disease. Cotinine was developed as an antidepressant as a fumaric acid salt, cotinine fumarate, to be sold under the brand name Scotine, but it was never marketed. — Wikipedia

Clinical trial activity

3 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2008 (NCT00879918)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Loading structure…

SMILES

CN1C(=O)CC[C@H]1c1cccnc1
Mol. weight
176.22 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • cotinine
  • cotinine
  • cotinine
  • cotinine
  • cotinine
  • cotinine
  • cotinine
  • (-)-cotinine
  • (s)-cotinine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02697227N/AAug 1, 2016National Institute on Drug Abuse (NIDA), University of Texas at Houston
NCT01058876Phase 1Dec 1, 2009University of California, San Francisco
NCT00879918Phase 1Dec 1, 2008University of California, San Francisco
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of California, San FranciscoAcademic/Hospital2212008
National Institute on Drug Abuse (NIDA)Government1012016
University of Texas at HoustonAcademic/Hospital1112016
3 organizations
Page 1 / 1